Standard

Ингибиторы натрий-глюкозного ко-транспортера 2-го типа: успешная погоня за двумя зайцами. / Перепеч, Никита Борисович; Михайлова, Ирина Евгеньевна.

в: РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ, Том 26, № S2, 2021, стр. 54-62.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Перепеч, НБ & Михайлова, ИЕ 2021, 'Ингибиторы натрий-глюкозного ко-транспортера 2-го типа: успешная погоня за двумя зайцами', РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ, Том. 26, № S2, стр. 54-62. https://doi.org/10.15829/1560-4071-2021-4534

APA

Перепеч, Н. Б., & Михайлова, И. Е. (2021). Ингибиторы натрий-глюкозного ко-транспортера 2-го типа: успешная погоня за двумя зайцами. РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ, 26(S2), 54-62. https://doi.org/10.15829/1560-4071-2021-4534

Vancouver

Перепеч НБ, Михайлова ИЕ. Ингибиторы натрий-глюкозного ко-транспортера 2-го типа: успешная погоня за двумя зайцами. РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ. 2021;26(S2):54-62. https://doi.org/10.15829/1560-4071-2021-4534

Author

Перепеч, Никита Борисович ; Михайлова, Ирина Евгеньевна. / Ингибиторы натрий-глюкозного ко-транспортера 2-го типа: успешная погоня за двумя зайцами. в: РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ. 2021 ; Том 26, № S2. стр. 54-62.

BibTeX

@article{4268133580c84648bb60c15a11a0ce3b,
title = "Ингибиторы натрий-глюкозного ко-транспортера 2-го типа:: успешная погоня за двумя зайцами",
abstract = "The review is devoted to the clinical efficacy of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Information on the mechanisms of drug action is given, as well as rationale for their use in the management of patients with diabetes and heart failure (HF) is provided. The results of large-scale randomized clinical trials evaluating the efficacy of SGLT2 inhibitors are discussed. We showed the beneficial effect of SGLT-2 inhibitors on the risk of cardiovascular events in patients with type 2 diabetes. In addition, an evidence of the ability of dapagliflozin and empagliflozin to improve the prognosis of patients with HF with reduced ejection fraction without diabetes are presented. The evidence and mechanisms of the nephroprotective action of SGLT2 inhibitors in patients with diabetes and HF are considered.",
keywords = "Diabetes, Heart failure, Prognosis, Sodium-glucose cotransporter type 2 inhibitors",
author = "Перепеч, {Никита Борисович} and Михайлова, {Ирина Евгеньевна}",
note = "Publisher Copyright: {\textcopyright} 2021, Silicea-Poligraf. All rights reserved.",
year = "2021",
doi = "10.15829/1560-4071-2021-4534",
language = "русский",
volume = "26",
pages = "54--62",
journal = " РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ",
issn = "1560-4071",
publisher = "Russian Society of Cardiology",
number = "S2",

}

RIS

TY - JOUR

T1 - Ингибиторы натрий-глюкозного ко-транспортера 2-го типа:

T2 - успешная погоня за двумя зайцами

AU - Перепеч, Никита Борисович

AU - Михайлова, Ирина Евгеньевна

N1 - Publisher Copyright: © 2021, Silicea-Poligraf. All rights reserved.

PY - 2021

Y1 - 2021

N2 - The review is devoted to the clinical efficacy of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Information on the mechanisms of drug action is given, as well as rationale for their use in the management of patients with diabetes and heart failure (HF) is provided. The results of large-scale randomized clinical trials evaluating the efficacy of SGLT2 inhibitors are discussed. We showed the beneficial effect of SGLT-2 inhibitors on the risk of cardiovascular events in patients with type 2 diabetes. In addition, an evidence of the ability of dapagliflozin and empagliflozin to improve the prognosis of patients with HF with reduced ejection fraction without diabetes are presented. The evidence and mechanisms of the nephroprotective action of SGLT2 inhibitors in patients with diabetes and HF are considered.

AB - The review is devoted to the clinical efficacy of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Information on the mechanisms of drug action is given, as well as rationale for their use in the management of patients with diabetes and heart failure (HF) is provided. The results of large-scale randomized clinical trials evaluating the efficacy of SGLT2 inhibitors are discussed. We showed the beneficial effect of SGLT-2 inhibitors on the risk of cardiovascular events in patients with type 2 diabetes. In addition, an evidence of the ability of dapagliflozin and empagliflozin to improve the prognosis of patients with HF with reduced ejection fraction without diabetes are presented. The evidence and mechanisms of the nephroprotective action of SGLT2 inhibitors in patients with diabetes and HF are considered.

KW - Diabetes

KW - Heart failure

KW - Prognosis

KW - Sodium-glucose cotransporter type 2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85117688050&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/ffe8141c-27ef-33d4-8e72-e7ed04a60a7e/

U2 - 10.15829/1560-4071-2021-4534

DO - 10.15829/1560-4071-2021-4534

M3 - статья

AN - SCOPUS:85117688050

VL - 26

SP - 54

EP - 62

JO - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

JF - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

SN - 1560-4071

IS - S2

ER -

ID: 88426009